株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性腎不全(ARF、急性腎障害):パイプライン分析

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 213122
出版日 ページ情報 英文 197 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.77円で換算しております。
急性腎不全(ARF、急性腎障害):パイプライン分析 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020
出版日: 2020年01月14日 ページ情報: 英文 197 Pages
概要

急性腎不全(ARF)とは、腎臓が血液から老廃物を濾過する機能が突然低下するという疾患です。主な症状には、眠気や息切れ、倦怠感、胸痛、また重篤な場合は痙攣や昏睡状態などがあります。主な疾病素質として、加齢や糖尿病、高血圧、心不全、腎疾患などが挙げられています。主な治療薬には抗生物質や利尿剤などがあります。

当レポートでは、世界各国での急性腎不全(急性腎障害)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

急性腎不全(ARF)の概要

治療薬の開発

  • 急性腎不全向けパイプライン製品:概要
  • 急性腎不全向けパイプライン製品:比較分析

各企業で開発中の急性腎不全治療薬

大学/研究機関で研究中の急性腎不全治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

急性腎不全治療薬:開発中の製品の一覧(企業別)

急性腎不全治療薬:研究中の製品の一覧(大学/研究機関別)

急性腎不全治療薬の開発に従事している企業

  • A1M Pharma AB
  • Adrenomed AG
  • Am-Pharma B.V.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Cellmid Limited
  • Complexa, Inc.
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • DURECT Corporation
  • F. Hoffmann-La Roche Ltd.
  • G1 Therapeutics, Inc.
  • Ischemix, Inc.
  • クリングルファーマ
  • NephroGenex, Inc.
  • NeuroVive Pharmaceutical AB
  • Noorik Biopharmaceuticals AG
  • Noxxon Pharma AG
  • Nyken B.V.
  • Orion Oyj
  • ProMetic Life Sciences Inc.
  • Quark Pharmaceuticals, Inc.
  • SBI Pharmaceuticals Co., Ltd.
  • Spherium Biomed S.L.
  • STATegics, Inc.
  • Thrasos Therapeutics Inc.
  • Torrent Pharmaceuticals Limited

急性腎不全:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (aminolevulinic acid hydrochloride + sodium ferrous citrate)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • A1M-001
  • AB-103
  • adrecizumab
  • BB-3
  • CAB-101
  • カルジオトロフィン-1
  • 腎障害向け Wnt7b活性化細胞療法
  • CMX-2043
  • CXA-10
  • cyclosporine
  • DM-199
  • DUR-928
  • HYPER-IL-6
  • KP-100IT
  • levosimendan
  • MG-53
  • MTP-131
  • N-003
  • NOXD-21
  • NYK-1341
  • PBI-4419
  • ピリドキサミン二塩酸塩
  • QPI-1002
  • R-190
  • 潰瘍性結腸炎・急性腎不全・敗血症・低ホスファターゼ血症向け遺伝子組み換え型ヒトアルカリホスファターゼの交換
  • 敗血症・炎症性大腸炎急性腎障害・急性放射線症候群・虚血性臓器障害向け遺伝子組み換え型タンパク質
  • RLS-003
  • RO-6839328
  • 急性腎障害・乳癌向け CDK4/CDK6 阻害小分子
  • 急性腎障害向け HDAC 阻害小分子
  • SP-15016
  • STSE-15
  • THR-184
  • TRC-160334

急性腎不全治療薬:パイプライン製品の最新動向

急性腎不全治療薬:開発が休止状態の製品

急性腎不全治療薬:開発が中止された製品

急性腎不全関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2020
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1 2020
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2020
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC11883IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 10, 31 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
  • Appendix